Onconova Therapeutics Inc. (NASDAQ: ONTX) was maintained as Neutral at Janney Capital Markets. This might sound dismal, but the firm’s fair value estimate was $3.00, versus a prior share price of $1.52. That had shares up more than 5% at $1.60 on Friday’s close. Janney said that Onconova announced the submission of CTAs for IV RIG as a treatment for HR-MDS with regulatory authorities is three EU countries, and this will soon be followed by CTAs in other European countries, as well as in Japan.
Rovi Corp. (NASDAQ: ROVI) may have missed the carnage last week due to a call from JPMorgan, and shares were under $10.00 when the call was made. The firm raised Rovi to Overweight from Neutral, but what stood out was its $23.00 price target. That was versus a $9.67 prior close and was against an end-of-the-week price of $10.98. While the new market cap was $954 million, the reality is that JPMorgan is just not known for calling on stocks to rise more than 100%. Shares may have to pull back $1 or so to qualify as truly being under $10.00 now, but this was a highly unusual call.
Telenav Inc. (NASDAQ: TNAV) may have been forgotten about by some investors, but the location-based platform services provider was started as Buy and was assigned a price target of $15.00 in a call from the boutique B. Riley. This was against a prior $6.77 close, and was against a $7.05 closing price on Friday. This sounds high as the street-high target against a 52-week range of $5.62 to $9.83, but Telenav has two other analysts covering it to generate a consensus price target of $12.33.
TerraForm Global Inc. (NASDAQ: GLBL) is just now getting analyst coverage, so investors need to understand there is limited operating history here. Citigroup started coverage as Buy with a $15 price target, and JPMorgan started it with an Overweight rating and $17 price target. For whatever it is worth, Goldman Sachs and Bank of America Merrill Lynch started coverage as Neutral. TerraForm was up 5.6% at $9.74 as Friday trading concluded, against a post-IPO range of $7.87 to $14.10.
Tilly’s Inc. (NYSE: TLYS) may have not had a great earnings report, but the teen and young adult apparel and accessories retailer was maintained as Buy at Roth Capital afterward. Investors will want to keep in mind that the formal price target was cut to $12 from $15 in the call, so it was not as if Roth issued a screaming Buy rating here. Still, it leaves more than 50% implied upside against Friday’s closing price of $7.86 after a 3.4% drop. Tilly’s has a 52-week range of $6.65 to $16.99, and its market cap is $220 million.